



DIABETES PATENTS

FREESTYLE INSULINX® SYSTEM



FREESTYLE LITE® SYSTEMS



FREESTYLE PRECISION NEO® SYSTEM



FREESTYLE LIBRE® GLUCOSE MONITORING SYSTEM



"This product(s) and/or its manufacture and/or its use either alone or in combination with other product(s) are protected by one or more of the following patents: US7,620,438; US7,826,382; US7,920,907; US8,106,780; US8,115,635; US8,223,021; US8,280,474; US8,358,210; US8,390,455; US8,409,093; US8,410,939; US8,542,122; US8,617,069; US8,688,188; US8,737,259; US8,760,297; US8,816,862; US8,915,850; US9,000,929; US9,007,781; US9,008,743; US9,042,955; US9,060,805; US9,184,875; US9,186,098; US9,186,113; US9,215,992; US9,226,714; US9,265,453; US9,271,670; US9,314,198; US9,336,423; US9,351,669; US9,402,544; US9,402,570; US9,474,475; US9,532,737; US9,549,694; US9,636,068; US9,687,183; US9,693,713; US9,750,444; US9,808,186; US9,831,985; US9,895,091; US9,907,470; US9,931,066; US9,980,669; US9,993,188; US10,010,280; US10,028,680; US10,136,816; US10,136,845; US10,178,954; US10,201,301; US10,213,139; US10,349,877; US10,492,685; US10,653,344; US10,736,547; US10,765,351; US10,820,842; US10,923,218; US10,952,611; US10,976,304; US11,017,890; US11,051,724; US11,103,165; US11,119,090; US11,179,068; US11,202,591; US11,207,006; US11,213,229; US11,266,335; US11,272,867; US11,363,975; US11,571,147; US11,627,898; US11,696,684; US11,806,141; USD882,432S; USD903,877S; USD915,601S; USD915,602S; USD955,432S; USD974,564S; USD980,986S; USD1,010,133S; RE47,315. Additional patents may be issued and/or pending."

FREESTYLE LIBRE® 2 GLUCOSE MONITORING SYSTEM



FREESTYLE LIBRE® 3 GLUCOSE MONITORING SYSTEM



FREESTYLE LIBRE PRO® GLUCOSE MONITORING SYSTEM



FREESTYLE LIBRELINK® APP



DEXCOM EXHIBIT 1052
Dexcom v. Abbott Diabetes
IPR2023-01409

LIBRELINKUP® APP



LIBREVIEW® DIABETES MANAGEMENT SYSTEM



POINT-OF-CARE SYSTEMS



PRECISION XTRA® SYSTEM



[CONSUMERS](#)

[HEALTHCARE
PROFESSIONALS](#)

[CAREERS](#)

[ABOUT ABBOTT](#)

[SUBSCRIBE](#)

[INVESTORS](#)

[NEWSROOM](#)

[RESPONSIBILITY](#)

[PARTNERS](#)

[CONTACTS](#)

[SITE MAP](#)

[GLOBAL WEBSITES](#)

[POLICIES](#)

[TERMS & CONDITIONS](#)

[PRIVACY POLICY](#)

[CONSUMER HEALTH
DATA PRIVACY POLICY](#)

[MYABBOTT PRIVACY
PREFERENCES](#)

[ADVERTISING
PREFERENCES](#)

[YOUR PRIVACY
CHOICES](#)

FOLLOW ABBOTT



© 2024 Abbott. All Rights Reserved. Please read the [Legal Notice](#) for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.





DIABETES PATENTS

FREESTYLE INSULINX® SYSTEM

FREESTYLE LITE® SYSTEMS

FREESTYLE PRECISION NEO® SYSTEM

FREESTYLE LIBRE® GLUCOSE MONITORING SYSTEM

FREESTYLE LIBRE® 2 GLUCOSE MONITORING SYSTEM

"This product(s) and/or its manufacture and/or its use either alone or in combination with other product(s) are protected by one or more of the following patents: US7,620,438; US7,826,382; US7,920,907; US8,106,780; US8,115,635; US8,223,021; US8,280,474; US8,358,210; US8,390,455; US8,409,093; US8,410,939; US8,542,122; US8,617,069; US8,688,188; US8,737,259; US8,760,297; US8,816,862; US8,915,850; US9,000,929; US9,007,781; US9,008,743; US9,042,955; US9,060,805; US9,184,875; US9,186,098; US9,186,113; US9,215,992; US9,226,714; US9,265,453; US9,271,670; US9,314,198; US9,336,423; US9,351,669; US9,402,544; US9,402,570; US9,474,475; US9,532,737; US9,549,694; US9,636,068; US9,687,183; US9,693,713; US9,750,444; US9,808,186; US9,831,985; US9,895,091; US9,907,470; US9,931,066; US9,980,669; US9,993,188; US10,010,280; US10,028,680; US10,136,816; US10,136,845; US10,178,954; US10,201,301; US10,213,139; US10,349,877; US10,492,685; US10,653,317; US10,653,344; US10,736,547; US10,765,351; US10,820,842; US10,918,342; US10,923,218; US10,952,611; US10,976,304; US11,006,870; US11,006,871; US11,017,890; US11,051,724; US11,103,165; US11,119,090; US11,179,068; US11,202,591; US11,205,511; US11,207,006; US11,213,229; US11,266,335; US11,272,867; US11,298,058; US11,363,975; US11,369,740; US11,534,089; US11,571,147; US11,586,273; US11,627,898; US11,793,936; US11,806,141; US11,872,370; USD882,432S; USD903,877S; USD915,601S; USD915,602S; USD954,740S; USD955,432S; USD955,435S; USD974,564S; USD980,986S; USD1,010,133S; RE47,315. Additional patents may be issued and/or pending."

FREESTYLE LIBRE® 3 GLUCOSE MONITORING SYSTEM

FREESTYLE LIBRE PRO® GLUCOSE MONITORING SYSTEM

FREESTYLE LIBRELINK® APP



LIBRELINKUP® APP



LIBREVIEW® DIABETES MANAGEMENT SYSTEM



POINT-OF-CARE SYSTEMS



PRECISION XTRA® SYSTEM



[CONSUMERS](#)

[HEALTHCARE
PROFESSIONALS](#)

[CAREERS](#)

[ABOUT ABBOTT](#)

[SUBSCRIBE](#)

[INVESTORS](#)

[NEWSROOM](#)

[RESPONSIBILITY](#)

[PARTNERS](#)

[CONTACTS](#)

[SITE MAP](#)

[GLOBAL WEBSITES](#)

[POLICIES](#)

[TERMS & CONDITIONS](#)

[PRIVACY POLICY](#)

[CONSUMER HEALTH
DATA PRIVACY POLICY](#)

[MYABBOTT PRIVACY
PREFERENCES](#)

[ADVERTISING
PREFERENCES](#)

[YOUR PRIVACY
CHOICES](#)

FOLLOW ABBOTT



© 2024 Abbott. All Rights Reserved. Please read the [Legal Notice](#) for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.





DIABETES PATENTS

FREESTYLE INSULINX® SYSTEM



FREESTYLE LITE® SYSTEMS



FREESTYLE PRECISION NEO® SYSTEM



FREESTYLE LIBRE® GLUCOSE MONITORING SYSTEM



FREESTYLE LIBRE® 2 GLUCOSE MONITORING SYSTEM



FREESTYLE LIBRE® 3 GLUCOSE MONITORING SYSTEM



"This product(s) and/or its manufacture and/or its use either alone or in combination with other product(s) are protected by one or more of the following patents: US7,826,382; US7,920,907; US8,280,474; US8,409,093; US8,617,069; US8,688,188; US8,737,259; US8,816,862; US8,915,850; US9,000,929; US9,007,781; US9,008,743; US9,042,955; US9,184,875; US9,186,098; US9,186,113; US9,215,992; US9,226,714; US9,265,453; US9,271,670; US9,314,198; US9,351,669; US9,402,544; US9,474,475; US9,549,694; US9,636,068; US9,687,183; US9,808,186; US9,831,985; US9,895,091; US10,136,816; US10,136,845; US10,178,954; US10,201,301; US10,349,877; US10,653,317; US10,653,344; US10,786,190; US10,820,842; US10,827,954; US10,918,342; US10,923,218; US10,952,611; US10,952,653; US11,006,870; US11,017,890; US11,071,478; US11,103,165; US11,116,431; US11,152,112; US11,202,591; US11,205,511; US11,207,006; US11,213,229; US11,266,335; US11,272,867; US11,272,890; US11,298,056; US11,298,058; US11,363,975; US11,369,740; US11,534,089; US11,571,147; US11,586,273; US11,627,898; US11,793,936; US11,806,141; US11,872,370; USD882,432S; USD955,433S; USD958,156S; USD966,333S; USD967,128S; USD967,136S; USD980,986S; USD982,762S; USD999,913S; USD1,002,852S; USD1,006,235S; RE47,315. Additional patents may be issued and/or pending."

FREESTYLE LIBRE PRO® GLUCOSE MONITORING SYSTEM



FREESTYLE LIBRELINK® APP



LIBRELINKUP® APP



LIBREVIEW® DIABETES MANAGEMENT SYSTEM



POINT-OF-CARE SYSTEMS



PRECISION XTRA® SYSTEM



[CONSUMERS](#)

[HEALTHCARE
PROFESSIONALS](#)

[CAREERS](#)

[ABOUT ABBOTT](#)

[SUBSCRIBE](#)

[INVESTORS](#)

[NEWSROOM](#)

[RESPONSIBILITY](#)

[PARTNERS](#)

[CONTACTS](#)

[SITE MAP](#)

[GLOBAL WEBSITES](#)

[POLICIES](#)

[TERMS & CONDITIONS](#)

[PRIVACY POLICY](#)


[CONSUMER HEALTH
DATA PRIVACY POLICY](#)

[MYABBOTT PRIVACY
PREFERENCES](#)

[ADVERTISING
PREFERENCES](#)

[YOUR PRIVACY
CHOICES](#)

FOLLOW ABBOTT



© 2024 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

